Clinical Trials Logo

Clinical Trial Summary

Acute chest syndrome is a severe respiratory complication of sickle cell disease.

The standard prevention of this dangerous complication is spirometry in wich patient is required to take deep breaths trough a little device several times a day. This treatment is compromised when pain in important or when the patient is asleep and cannot participate.

The investigators hypothesised that non invasive ventilation in wich patient have no effort to take might be a better prevention than spirometry and may improve pain and quality of sleep.

Children with vaso-occlusive crisis necessitating morphinic treatment will be randomly assigned with either spirometry or ventilation and the investigators will monitor for occurrence of acute chest syndrome, pain and quality of sleep.


Clinical Trial Description

Acute chest syndrome is a severe complication of sickle cell disease. Several factors can contribute to this complication including infections, vaso-occlusive crisis, important pain that may give shortness of breath and morphinic treatments as they may cause hypoventilation.

The standard prevention of this dangerous complication is incentive spirometry in wich patient is required to take deep breaths trough a little device several times a day. This treatment is compromised when pain in important or when the patient is asleep and cannot participate.

In patients who have had surgery who have also pain and morphinic treatments, non invasive ventilation have proven a good option for preventing pulmonary complications.

Besides, our experience in non invasive ventilation for treatment of acute chest syndrome show a good tolerance and efficiency. It also seems to help with pain management.

The investigators hypothesised that non invasive ventilation in wich patient have no effort to take might be a better prevention than incentive spirometry and may improve pain and quality of sleep.

After informed consent, patients aged from 6 to 20 years old with SS or S-Beta sickle cell disease with vaso-occlusive crisis necessitating morphinic treatment hospitalised in intensive care unit in Necker Hospital for Sick Children (Paris) will be randomly assigned with either spirometry or ventilation. It is a monocentric study.

Patients with acute chest syndrome, oxygen needs, pneumonia or other condition requiring ventilation at presentation will not be included.

Spirometry will be realised through volumetric devices, every two hours during the day with 10 maximum inspirations and at night if the patient is awake.

Non invasive ventilation will be applied through a nasal mask with VS III machines from Resmed®, at least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.

The investigators will monitor for occurrence of acute chest syndrome, pain, morphinic requirements, length of hospital stay, comfort, quality of sleep The treatment will be continued until morphinic treatment is stopped. The investigators intend to include 60 patients in each arm to show a difference of 25% in the occurrence of acute chest syndrome (primary judgement criteria).

Acute chest syndrome will be defined according to the criteria used by Vichinsky (Vichinsky, E. P. et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 89, 1787-1792 (1997) The investigators will aslo compare morphinic requirements, length of hospital stay and quality of sleep as secondary judgment criteria. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01501643
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Terminated
Phase N/A
Start date November 2011
Completion date April 2015

See also
  Status Clinical Trial Phase
Recruiting NCT03639805 - Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis N/A
Withdrawn NCT00711698 - Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) Phase 2
Recruiting NCT05289700 - Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) Phase 3
Recruiting NCT03412045 - Hyperbaric Oxygen Therapy in Sickle Cell Pain N/A
Recruiting NCT05376046 - Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Active, not recruiting NCT04935879 - A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Phase 3
Terminated NCT01891812 - Nitrous Oxide Analgesia Vaso-occlusive Crisis Phase 2
Completed NCT04301336 - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Phase 2/Phase 3
Completed NCT01737814 - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Phase 3
Completed NCT01419977 - Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo Phase 2
Completed NCT01119833 - Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis Phase 2
Not yet recruiting NCT06181695 - Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Phase 3
Recruiting NCT05378555 - Oral Ketamine for Treatment of Vaso-Occlusive Pain Phase 3
Completed NCT04756375 - Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room N/A
Active, not recruiting NCT05348915 - A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Phase 3
Enrolling by invitation NCT06345638 - Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
Completed NCT03296345 - Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis Phase 2
Terminated NCT02179177 - Apixaban in Patients With Sickle Cell Disease Phase 3
Recruiting NCT03353584 - Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease N/A
Terminated NCT01522196 - A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. Phase 2